510(k) Report

510(k) · Cleared

Cleared

Quantia IgE

K214068510(k) SpecialCleared Feb 21, 2023421-day reviewClass II21 CFR 866.5510

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Biokit, S.A. · DGC Ige, Antigen, Antiserum, Control

Cleared on Feb 21, 2023 as substantially equivalent to K050493 (Biokit, S.A., 2005) after a 421-day review. Its family tree reaches back 2 generations to 1997.

Decided
Feb 21, 2023
Review
421 days
Class
Class II
Product code
DGC
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K964152 (1997). No later device cites it as a predicate yet.

  1. Root · 2 generations backK964152 Unicap Total Ige Assay/Pharmacia Total Ige Controls LMHPharmacia, Inc. · 1997
  2. 1 generation backK050493 Quantia IgeBiokit, S.A. · 2005
  3. This deviceK214068 Quantia IgEBiokit, S.A. · 2023
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K964152Unicap Total Ige Assay/Pharmacia Total Ige Controls LMHPharmacia, Inc.1997—
−1K050493Quantia IgeBiokit, S.A.2005—
0 (this device)K214068Quantia IgEBiokit, S.A.2023—
FIG. 1 — Lineage of K214068, 1997–2023Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in DGC? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new DGC device

  1. #1 K231151 Kenota 1 Total IgE; Kenota 1 (instrument)score 8.0 · 3 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K050493Quantia Ige
Summary page 4
…Product Code DGC Classification Panel Immunology Predicate Device K050493 Quantia IgE The Quantia IgE reagent is a suspension of polystyrene lat…
Biokit, S.A.2005—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 26 years and passes through 2 companies; a new generation was cleared every 17.5 years on median.
  • None of the 2 ancestors has a recall.

How does its category compare?

All DGC devices

DGC Ige, Antigen, Antiserum, Control: FDA decisions, review times, recalls and adverse event reports over 20 years. 2023, this device’s year, is highlighted.

FDA decisions per year · DGC

1in 2024

2007: 12014: 12016: 12020: 12022: 12023: 12024: 1
2007high 1 (2007) · low 0 (2008)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · DGC

Too few DGC 510(k)s in any year since 2007 to give a median.

Recalls per year · DGC

1in 2016

2009: 12016: 1
2007high 1 (2009) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · DGC

2in 2021

2008: 22009: 52010: 122011: 132013: 12014: 12015: 22016: 22021: 2
2007high 13 (2011) · low 0 (2007)2025

MAUDE reports naming product code DGC, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—00
20080—02
20090—15
20100—012
20110—013
20120—00
20130—01
20141—01
20150—02
20161—12
20170—00
20180—00
20190—00
20201—00
20210—02
20221—00
20231—00
20241—00
20250—00
20260—0—

What is it indicated for?

Automated latex enhanced immunoassay for the quantitative in vitro determination of total immunoglobulin E (IgE) in human serum or plasma (EDTA, heparin, citrate) using the ARCHITECT c Systems. The measurement of total IgE is useful in the clinical diagnosis of IgE-mediated allergies, if used in conjunction with other clinical studies.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K214068: Quantia IgE.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K214068

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026